Sarepta Therapeutics Company Profile (NASDAQ:AVII)

About Sarepta Therapeutics (NASDAQ:AVII)

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Industry, Sector and Symbol:
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: N/A
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -180.07%
 

Frequently Asked Questions for Sarepta Therapeutics (NASDAQ:AVII)

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "AVII."

Who are some of Sarepta Therapeutics' key competitors?

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:

  • Douglas S. Ingram, President, Chief Executive Officer
  • Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer
  • David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary
  • Alexander Cumbo, Senior Vice President, Global Commercial Development
  • Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality
  • Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer
  • Richard J. Barry, Independent Director
  • M. Kathleen Behrens Ph.D., Independent Director
  • Claude Nicaise M.D., Independent Director
  • Hans Wigzell M.D., Ph.D., Independent Director

How do I buy Sarepta Therapeutics stock?

Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of Sarepta Therapeutics stock can currently be purchased for approximately $0.66.


MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ AVII)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  25 (Vote Underperform)
Total Votes:  65
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:AVII) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:AVII)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Sarepta Therapeutics (NASDAQ:AVII)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Sarepta Therapeutics (NASDAQ:AVII)
Current Year EPS Consensus Estimate: $-0.270 EPS

Dividends

Dividend History for Sarepta Therapeutics (NASDAQ:AVII)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sarepta Therapeutics (NASDAQ:AVII)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Sarepta Therapeutics (NASDAQ:AVII)
Latest Headlines for Sarepta Therapeutics (NASDAQ:AVII)
Source:
DateHeadline
investorplace.com logoSarepta Therapeutics Inc (SRPT) Stock Heads Higher on Analyst Upgrade
investorplace.com - March 2 at 1:31 PM
feeds.benzinga.com logoSarepta Under Pressure As FDA Approves Marathon Pharma's Emflaza For DMD Treatment
feeds.benzinga.com - February 9 at 3:46 PM
feeds.benzinga.com logoSarepta Soars Following Encouraging Exondys 51 News
feeds.benzinga.com - January 10 at 12:48 PM
forbes.com logoNoteworthy Wednesday Option Activity: SRPT, DAL, C
www.forbes.com - December 14 at 5:43 PM
feeds.benzinga.com logoSarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen
feeds.benzinga.com - October 7 at 12:54 PM
feeds.benzinga.com logoSarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
feeds.benzinga.com - October 4 at 10:21 AM
feeds.benzinga.com logoSarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug
feeds.benzinga.com - September 29 at 8:19 AM
fool.com logoBetter Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc
www.fool.com - September 28 at 1:16 PM
feeds.benzinga.com logo3 Reasons Sarepta Shares Rallied Following News Of $225 Million Offering
feeds.benzinga.com - September 22 at 3:49 PM
feeds.benzinga.com logoFDA Commish Says Sarepta's DMD Study Should Be Retracted
feeds.benzinga.com - September 22 at 10:58 AM
investorplace.com logoWhy Infoblox Inc (BLOX), Isle of Capri Casinos (ISLE) and Sarepta Therapeutics Inc (SRPT) Are 3 of Today’s Best Stocks
investorplace.com - September 19 at 5:58 PM
feeds.benzinga.com logoSarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval
feeds.benzinga.com - September 19 at 3:50 PM
feeds.benzinga.com logoOppenheimer Weighs In on Sarepta's Eteplirsen
feeds.benzinga.com - September 19 at 12:47 PM
investorplace.com logoWhy Monsanto Company (MON), Sarepta Therapeutics Inc (SRPT) and VF Corp (VFC) Are 3 of Today’s Worst Stocks
investorplace.com - September 15 at 4:54 PM
reuters.com logoIndia close to signing Rafale jet deal: government official
www.reuters.com - September 15 at 12:33 PM
feeds.benzinga.com logoExclusive: Dr. Ron Farkas, Eteplirsen's Harshest Critic, Has Left The FDA
feeds.benzinga.com - September 13 at 9:48 PM
forbes.com logoNoteworthy Friday Option Activity: SRPT, NUS, IBM
www.forbes.com - August 5 at 12:31 PM
feeds.benzinga.com logoWatch These 10 Huge Put Purchases In Thursday Trade
feeds.benzinga.com - July 28 at 3:54 AM
fool.com logoSarepta Therapeutics Inc's Stock Has Plunged 47% in 2016. Here's Why.
www.fool.com - July 4 at 8:24 AM
thestreet.com logoShort Interest In Sarepta Therapeutics Moves 15% Higher
www.thestreet.com - February 27 at 2:50 PM
bidnessetc.com logoHere Is Why Sarepta Therapeutics Inc Slid Today
www.bidnessetc.com - February 9 at 2:33 PM
streetinsider.com logoSarepta Therapeutics (SRPT) PDUFA for Eteplirsen Extended
www.streetinsider.com - February 8 at 2:40 PM
prnewswire.com logoCovered Call Alerts For Apple, Sarepta Therapeutics, Freeport-McMoRan, PayPal Holdings Inc. and Vuzix Corporation Released By InvestorsObserver
www.prnewswire.com - February 4 at 2:55 PM
rttnews.com logoSarepta Therapeutics Inc. (SRPT) Plunged To An 8-Month Low
www.rttnews.com - January 20 at 2:23 PM
nasdaq.com logoSarepta Therapeutics Inc. (SRPT) Is Sinking After FDA Rejects BioMarin Drug
www.nasdaq.com - January 17 at 1:55 PM
investopedia.com logoSarepta Therapeutics Made Investors Millionaires in 2 Years
www.investopedia.com - August 14 at 12:01 PM

Social

Chart

Sarepta Therapeutics (AVII) Chart for Saturday, August, 19, 2017

This page was last updated on 8/19/2017 by MarketBeat.com Staff